Accurate imaging in the processes of formation and inhibition of drug-induced liver injury by an activable fluorescent probe for ONOO

被引:6
|
作者
Dong, Junming [1 ]
Yang, Yushun [2 ]
Fan, Xiangjun [3 ]
Zhu, Hai-Liang [1 ]
Li, Zhen [1 ]
机构
[1] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, 163 Xianlin Ave, Nanjing 210023, Peoples R China
[2] Jinhua Adv Res Inst, Jinhua 321019, Peoples R China
[3] Nantong Univ, Dept Gen Surg, Affiliated Hosp, Nantong 226001, Peoples R China
关键词
Fluorescent probe; Detection of peroxynitrite; Drug -induced liver injury; Accurate real-time imaging; PEROXYNITRITE; DIAGNOSIS; BIOLOGY; CELLS; METABOLISM; MECHANISMS; MARKERS;
D O I
10.1016/j.mtbio.2023.100689
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Herein, an activable fluorescent probe for peroxynitrite (ONOO-), named NOP, was constructed for the accurate imaging in the processes of formation and inhibition of drug-induced liver injury induced by Acetaminophen (APAP). During the in-solution tests on the general optical properties, the probe showed advantages including good stability, wide pH adaption, high specificity and sensitivity in the monitoring of ONOO-. Subsequently, the probe was further applied in the model mice which used APAP to induce the injury and used inhibiting agents (GSH, Glu, NAC) to treat the induced injury. The construction of the liver injury model was confirmed by the pathological staining and the serum indexes including ALT, AST, ALP, TBIL as well as LDH. During the formation of the drug-induced liver injury, the fluorescence in the red channel enhanced in both time-dependent and dosedependent manners. In inhibition tests, the inhibition of the liver injury exhibited the reduction of the fluorescence intensity. Therefore, NOP could achieve the accurate imaging in the processes of formation and inhibition of drug-induced liver injury. The information here might be helpful for the early diagnosis and the screening of potent treating candidates in liver injury cases.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Drug-Induced Liver Injury
    Leise, Michael D.
    Poterucha, John J.
    Talwalkar, Jayant A.
    MAYO CLINIC PROCEEDINGS, 2014, 89 (01) : 95 - 106
  • [32] Drug-Induced Liver Injury
    McAtee, Cathy
    CRITICAL CARE NURSING CLINICS OF NORTH AMERICA, 2022, 34 (03) : 267 - 275
  • [33] Drug-Induced Liver Injury
    Almario, Eileen E. N.
    Borlak, Juergen
    Suzuki, Ayako
    Chen, Minjun
    BIOMED RESEARCH INTERNATIONAL, 2017, 2017
  • [34] Drug-induced liver injury
    Denk, H
    PATHOLOGY OF THE KIDNEYS AND URINARY PASSAGES - MOLECULAR VASCULAR PATHOLOGY AND ANGIOGENESIS, 2002, 86 : 120 - 125
  • [35] Drug-induced liver injury
    Aithal, G.
    DRUG SAFETY, 2017, 40 (10) : 1040 - 1040
  • [36] Drug-induced liver injury
    Kumachev, Alexander
    Wu, Peter E.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2021, 193 (09) : E310 - E310
  • [37] Drug-induced liver injury
    Andrade, Raul J.
    Chalasani, Naga
    Bjornsson, Einar S.
    Suzuki, Ayako
    Kullak-Ublick, Gerd A.
    Watkins, Paul B.
    Devarbhavi, Harshad
    Merz, Michael
    Isabel Lucena, M.
    Kaplowitz, Neil
    Aithal, Guruprasad P.
    NATURE REVIEWS DISEASE PRIMERS, 2019, 5 (1)
  • [38] Drug-induced liver injury
    Grant, Lafaine M.
    Rockey, Don C.
    CURRENT OPINION IN GASTROENTEROLOGY, 2012, 28 (03) : 198 - 202
  • [39] Drug-Induced Liver Injury
    Hamilton, Leslie A.
    Collins-Yoder, Angela
    Collins, Rachel E.
    AACN ADVANCED CRITICAL CARE, 2016, 27 (04) : 430 - 440